OTCMKTS:BTHEBoston Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Boston Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.01 0.00 (0.00 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.01Now: $0.01▼$0.0150-Day Range$0.01MA: $0.01▼$0.0252-Week Range$0.01Now: $0.01▼$0.03Volume22,000 shsAverage Volume14,611 shsMarket Capitalization$1.44 millionP/E RatioN/ADividend YieldN/ABeta0.15 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based, injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also develops OxyFex, an oxygen delivery agent for ischemia and trauma for blood loss during surgery in veterinary medicine applications. In addition, it produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Boston Therapeutics. Previous Next 2.6 Community Rank Outperform VotesBoston Therapeutics has received 106 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBoston Therapeutics has received 101 “underperform” votes. (Add your “underperform” vote.)Community SentimentBoston Therapeutics has received 51.21% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Boston Therapeutics and other stocks. Vote “Outperform” if you believe BTHE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BTHE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBoston Therapeutics does not currently pay a dividend.Dividend GrowthBoston Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Boston Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.65% of the stock of Boston Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BTHE Previous Symbol CUSIPN/A CIK1473579 Webwww.bostonti.com Phone603-935-9799Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales72.23 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-0.19Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,690,000.00 Net Margins-22,271.80% Return on EquityN/A Return on Assets-586.87%Miscellaneous Employees2 Outstanding Shares111,130,000Market Cap$1.44 million Next Earnings DateN/A OptionableNot Optionable OTC:BTHE Rates by TradingView Receive BTHE News and Ratings via Email Sign-up to receive the latest news and ratings for BTHE and its competitors with MarketBeat's FREE daily newsletter. Boston Therapeutics (OTCMKTS:BTHE) Frequently Asked Questions How has Boston Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Boston Therapeutics' stock was trading at $0.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BTHE stock has increased by 30.0% and is now trading at $0.0130. View which stocks have been most impacted by Coronavirus. How were Boston Therapeutics' earnings last quarter? Boston Therapeutics Inc (OTCMKTS:BTHE) released its quarterly earnings data on Monday, May, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million for the quarter. View Boston Therapeutics' earnings history. Has Boston Therapeutics been receiving favorable news coverage? News stories about BTHE stock have been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Boston Therapeutics earned a news impact score of 1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Boston Therapeutics. Who are some of Boston Therapeutics' key competitors? Some companies that are related to Boston Therapeutics include Parnell Pharmaceuticals (PARNF), Sienna Biopharmaceuticals (SNNA), iCo Therapeutics (ICOTF), Auris Medical (EARS), Innovus Pharmaceuticals (INNV), Wize Pharma (WIZP), IntelliPharmaCeutics Intl (IPCIF), MusclePharm (MSLP), Innovus Pharmaceuticals (INNVD), Global Future City (FTCY), Peak Pharmaceuticals (PKPH), Sienna Biopharmaceuticals (MLNTQ), Respirerx Pharmaceuticals (RSPI), Earth Science Tech (ETST) and Praxsyn (PXYN). View all competitors. What other stocks do shareholders of Boston Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Therapeutics investors own include Dynavax Technologies (DVAX), NeXt Innovation (GSVC), InterCloud Systems (ICLD), Inpixon (INPX), PositiveID (PSID), Firsthand Technology Value Fund (SVVC), Arca Biopharma (ABIO), Acorn Energy (ACFN), Apollo Investment (AINV) and Ambarella (AMBA). Who are Boston Therapeutics' key executives? Boston Therapeutics' management team includes the following people: Mr. Carl W. Rausch, CEO, CFO & Director (Age 70)Dr. Meng Hee Tan, Consulting Medical Director What is Boston Therapeutics' stock symbol? Boston Therapeutics trades on the OTCMKTS under the ticker symbol "BTHE." How do I buy shares of Boston Therapeutics? Shares of BTHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Boston Therapeutics' stock price today? One share of BTHE stock can currently be purchased for approximately $0.01. How big of a company is Boston Therapeutics? Boston Therapeutics has a market capitalization of $1.44 million and generates $20,000.00 in revenue each year. Boston Therapeutics employs 2 workers across the globe. What is Boston Therapeutics' official website? The official website for Boston Therapeutics is www.bostonti.com. How can I contact Boston Therapeutics? Boston Therapeutics' mailing address is 354 MERRIMACK STREET #4, LAWRENCE MA, 01843. The company can be reached via phone at 603-935-9799 or via email at [email protected] This page was last updated on 7/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
